secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001157523-21-001387
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506
---------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.
- R&D expenses $9.9M (Q3 2021) vs $3.2M (Q3 2020), increase due to Phase 1 trial and headcount.
- Net loss $12.9M ($0.26/share) compared to $3.6M in Q3 2020.
- Positive EDG-5506 Phase 1 MAD topline: well tolerated, target engagement, no effect on voluntary strength or cardiac myosin.
- First BMD patients dosed in Phase 1b; Phase 2 trials in BMD and DMD expected to start in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/0001157523-21-001387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/a52527144.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-001387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer